BASF Planning Major Polyurethane Capacity Increases in North America

BASF plans to increase the existing production capacities for polyols at its Verbund site in Geismar, Louisiana. Polyols are propylene oxide-based materials used to manufacture polyurethane products. BASF will construct two new reactors and revamp two existing reactors used to manufacture polyols. A new logistics center will also be built for polyurethane basic products and other chemicals. The total investment for these measures is about $125 million.

In addition, BASF plans to transfer a major part of the polyol production from its site in Wyandotte, Michigan, to Geismar. These measures will lead to an increase in the annual capacity of polyols in the U.S. from currently 250,000 metric tons (including external tolling arrangements and purchases) to 350,000 metric tons in 2008. BASF’s own capacity will better support the existing business and replaces to a large extent external tolling arrangements and purchases.

BASF has also successfully completed its acquisition of a dinitrotoluene (DNT) manufacturing plant in Geismar from Air Products and Chemicals Inc., Pennsylvania, for $155 million. The transaction has already received all necessary regulatory approvals. DNT is an important raw material for the production of toluene diisocyanate (TDI), a polyurethane basic material used in various applications such as seat cushioning foams for furniture and automobiles. The DNT plant will supply BASF’s TDI plant in Geismar, which has an annual capacity of 160,000 metric tons.

“Our investments at the Geismar site underline our commitment to the polyurethane market in North America,” said Bill Bernstein, Group Vice President of BASF’s polyurethanes business in North America. “These measures will improve the effectiveness of our polyol and TDI manufacturing at Geismar, and will secure a reliable supply of high-quality products to our customers in the long run.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.